This clinical trial is focused on studying a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. The study is testing a treatment called Batoclimab, which is a solution for injection. Batoclimab is also known by its code name IMVT-1401. The trial will compare the effects of Batoclimab to a placebo in adult participants who have active CIDP.

The purpose of the study is to evaluate how effective Batoclimab is in maintaining a clinical response in people with CIDP who are already receiving treatments like immune globulin or plasma exchange. Participants will be randomly assigned to receive either Batoclimab or a placebo. The study will be conducted over a period of time, and participants will receive regular injections. The trial aims to see if Batoclimab can help prevent relapses, which are periods when symptoms worsen.

Throughout the study, participants will be monitored to assess their response to the treatment. This will include checking for any changes in their condition and measuring their strength and ability to perform daily activities. The study will help determine if Batoclimab is a safe and effective treatment option for people with CIDP.